Inventor · disambiguated record
Harpreet K. Sandhu
Also filed as: SANDHU HARPREET · SANDHU HARPREET K · SANDHU HARPREET KAUR
19 granted patents·25 pending applications·195 citations·filing 1999–2024
93Inventor score
Files withHOFFMANN LA ROCHE18CHATTERJI ASHISH9AMNEAL COMPLEX PRODUCTS RES LLC4PLEXXIKON INC3KASHIV BIOSCIENCES LLC2
Top patents by PatentIndex Score
44 records- 0195US9663517B2Compositions and uses thereofPLEXXIKON INC·Filed 2016·Granted May 30, 2017·31 cites·5 claims
- 0292US9447089B2Compositions and uses thereofDESAI DIPEN·Filed 2010·Granted Sep 20, 2016·46 cites·29 claims
- 0389US11318091B2Gastroretentive dosage forms for sustained drug deliveryAMNEAL COMPLEX PRODUCTS RES LLC·Filed 2021·Granted May 3, 2022·1 cites·20 claims
- 0489US6350786B1Stable complexes of poorly soluble compounds in ionic polymersHOFFMANN LA ROCHE·Filed 1999·Granted Feb 26, 2002·94 cites·33 claims
- 0587US11007145B2Gastroretentive dosage forms for sustained drug deliveryKASHIV SPECIALTY PHARMACEUTICALS LLC·Filed 2020·Granted May 18, 2021·1 cites·14 claims
- 0686US10918597B2Gastroretentive dosage forms for sustained drug deliveryKASHIV PHARMA LLC·Filed 2018·Granted Feb 16, 2021·1 cites·27 claims
- 0786US2025073216A1Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) AntagonistsHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 0886US2024335376A1Gastroretentive dosage forms for sustained drug deliveryAMNEAL COMPLEX PRODUCTS RES LLC·Filed 2024·Application pending·0 cites
- 0985US12042559B2Gastroretentive dosage forms for sustained drug deliveryAMNEAL COMPLEX PRODUCTS RES LLC·Filed 2023·Granted Jul 23, 2024·0 cites·20 claims
- 1085US10857098B2Gastroretentive dosage forms for sustained drug deliveryKASHIV BIOSCIENCES LLC·Filed 2020·Granted Dec 8, 2020·1 cites·14 claims
- 1184US6486329B1Amorphous form of cell cycle inhibitor having improved solubility and bioavailabilityHOFFMANN LA ROCHE·Filed 2002·Granted Nov 26, 2002·10 cites·4 claims
- 1280US2022218604A1Gastroretentive dosage forms for sustained drug deliveryAMNEAL COMPLEX PRODUCTS RES LLC·Filed 2022·Application pending·0 cites
- 1377US10034854B2Pharmaceutical composition with improved bioavailabilityHOFFMANN LA ROCHE·Filed 2016·Granted Jul 31, 2018·3 cites·7 claims
- 1471US9427427B2Pharmaceutical composition with improved bioavailabilityHOFFMANN LA ROCHE·Filed 2014·Granted Aug 30, 2016·2 cites·21 claims
- 1570US2020330600A1Pharmaceutical compositionHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 1670US2022241260A9Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) AntagonistsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 1764US2015209294A1Pharmaceutical composition and processHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 1864US2019216789A1Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) AntagonistsHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 1963US6469179B1Amorphous form of cell cycle inhibitor having improved solubility and bioavailabilityHOFFMANN LA ROCHE·Filed 2002·Granted Oct 22, 2002·2 cites·2 claims
- 2062US6482847B2Amorphous form of cell cycle inhibitor having improved solubility and bioavailabilityHOFFMANN LA ROCHE·Filed 2001·Granted Nov 19, 2002·1 cites·9 claims
- 2161US2019241557A1Compositions and uses thereofPLEXXIKON INC·Filed 2018·Application pending·0 cites
- 2260US2015140087A1Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) AntagonistsHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 2358US2018111930A1Compositions and uses thereofPLEXXIKON INC·Filed 2017·Application pending·0 cites
- 2457US2007184113A1Pharmaceutical composition and processCHATTERJI ASHISH·Filed 2007·Application pending·0 cites
- 2556US10744131B2Abuse-resistant drug formulationsKASHIV BIOSCIENCES LLC·Filed 2014·Granted Aug 18, 2020·0 cites·20 claims
- 2656US2008293787A1Pharmaceutical compositions for poorly soluble drugsCHATTERJI ASHISH·Filed 2008·Application pending·0 cites
- 2756US2012129898A1Pharmaceutical compositions for poorly soluble drugsCHATTERJI ASHISH·Filed 2012·Application pending·0 cites
- 2855US2011245305A1Pharmaceutical compositions for poorly soluble drugsCHATTERJI ASHISH·Filed 2011·Application pending·0 cites
- 2955US2017202819A1Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonistsHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 3054US2018369388A1Pharmaceutical compositionHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 3153US6469180B1Amorphous form of cell inhibitor having improved solubility and bioavailabilityHOFFMANN LA ROCHE·Filed 2002·Granted Oct 22, 2002·0 cites·3 claims
- 3253US2013172375A1Pharmaceutical compositionHOFFMANN LA ROCHE·Filed 2012·Application pending·0 cites
- 3353US2006177503A1Bambuterol and integrin inhibitor combination and treatment methodRAMES ALEXIS·Filed 2006·Application pending·0 cites
- 3453US2011028524A1Pharmaceutical compositions for poorly soluble drugsCHATTERJI ASHISH·Filed 2010·Application pending·0 cites
- 3553US2006198889A1Roflumilast and integrin inhibitor combination and treatement methodSANDHU HARPREET K·Filed 2006·Application pending·0 cites
- 3647US2014128431A1Pharmaceutical composition with improved bioavailability, safety and tolerabilityHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 3746US10695296B2Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredientASANA BIOSCIENCES LLC·Filed 2018·Granted Jun 30, 2020·0 cites·28 claims
- 3846US2012039999A1Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonistsCHATTERJI ASHISH·Filed 2011·Application pending·0 cites
- 3945US10960001B2Opioid agonist / antagonist combination dosage formsKASHIV PHARMA LLC·Filed 2018·Granted Mar 30, 2021·0 cites·6 claims
- 4042US2006134217A1Leukotriene and integrin inhibitor combination and treatment methodSANDHU HARPREET K·Filed 2005·Application pending·0 cites
- 4139US6492530B1Amorphous form of cell cycle inhibitor having improved solubility and bioavailabilityHOFFMANN LA ROCHE·Filed 2002·Granted Dec 10, 2002·2 cites·2 claims
- 4235US8222230B2Pharmaceutical compositions with superior product performance and patient complianceCHATTERJI ASHISH·Filed 2010·Granted Jul 17, 2012·0 cites·21 claims
- 4333US2012213827A1Process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusionCHATTERJI ASHISH·Filed 2012·Application pending·0 cites
- 4427US2012040008A1Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonistsCHATTERJI ASHISH·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →